Original Article
The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia
N Engl J Med 2004; 350:1405-1413April 1, 2004
- Abstract
Background
Although the standard treatment of oral leukoplakia ranges from watchful waiting to complete resection, the value of these approaches is unknown.
Methods
We studied the relations among resection, ploidy status, and death from cancer in 103 patients with diploid dysplastic oral leukoplakia, 20 patients with tetraploid lesions, and 27 patients with aneuploid lesions. Data on cancer-specific mortality and treatment were obtained from the Cancer Registry of Norway, Statistics Norway, and chart reviews.
Results
Primary oral carcinoma developed in 47 of the 150 patients with leukoplakia (31 percent) — 5 with diploid, 16 with tetraploid, and 26 with aneuploid leukoplakia — during a mean follow-up of 80 months (range, 4 to 237). The margin status of the initial leukoplakia resection had no relation to the development of oral cancer (P=0.95). Twenty-six of the 47 patients in whom cancer developed (4 with prior tetraploid and 22 with prior aneuploid lesions) had recurrences (55 percent); the recurrences were more frequently multiple and distant (within the oral cavity) among patients with aneuploid lesions than among those with tetraploid or diploid lesions. All 47 patients underwent a standard regimen of surgery and radiation, followed by chemotherapy in the 26 with recurrent cancer. Only patients with aneuploid leukoplakia died of oral cancer; the five-year rate of death from cancer was 72 percent. Aneuploidy-related first carcinomas were diagnosed at a more advanced stage than were carcinomas originating from diploid or tetraploid leukoplakia (P=0.03) and were more likely to be lethal regardless of the stage.
Conclusions
Complete resection of aneuploid leukoplakia does not reduce the high risk of aggressive carcinoma and death from oral cancer.
Media in This Article
Figure 1
Course of Events in 150 Patients with Dysplastic Oral Leukoplakia from the Time of the First Biopsy (Panel A) and Course of Events from the Time of the Development of the First Cancer in the 47 Patients with Oral Cancers (Panel B), According to Ploidy Status.Figure 2
Clinical Course of Oral Leukoplakia, According to the Presence (Aneuploidy and Tetraploidy) or Absence (Diploidy) of Markers of Genomic Instability.Article Activity
- Article
The standard treatment of oral leukoplakia ranges from watchful waiting to complete resection.1,2 There is little evidence, however, that resecting precursor lesions of oral leukoplakia prevents oral cancer.3,4 Oral carcinogenesis is a complex, multifocal process of multiclonal field carcinogenesis and intraepithelial clonal spread.5-8 The multifocal nature of the early process may reduce the efficacy of local treatment.9-11
The cancer-specific mortality among patients with oral carcinomas that develop from aneuploid oral erythroplakia, which is clinically more aggressive than the far more common oral leukoplakia,12,13 is substantial.14 We previously found that a carcinoma developed in 36 of 150 patients with oral leukoplakia (24 percent) during a follow-up that exceeded 10 years in some cases and that a carcinoma developed in approximately 70 percent of patients with aneuploid oral leukoplakia within 3 years.15 In the current study, we determined the effect of resecting oral leukoplakia on the rates of primary cancer, new or subsequent cancer, and death from oral cancer. We also evaluated the topographic relation between leukoplakias and their related cancers.
Methods
Clinical and Pathological Assessment
We used the Systematized Nomenclature of Medicine (SNOMED) coding system to identify the sites of leukoplakia and carcinoma.16 The status of the resection margins was determined after consensus had been reached by four pathologists who conducted independent evaluations. Cancers that occurred after treatment of the first cancer were defined as new or subsequent cancers, since we did not determine whether they represented a recurrence or a second primary cancer. Information regarding the treatment of patients during follow-up was obtained by chart review. Oral squamous-cell carcinomas were graded according to the criteria of the World Health Organization.17 The criteria of the American Joint Committee on Cancer were used to determine the clinical stage.18
Assessment of New Cancers and Cancer-Specific Mortality
We used the data base of the Cancer Registry of Norway to assess cancer-specific mortality. All patients included in the study provided written or oral informed consent that follow-up data could be used for research purposes. The basis of the registry, which was created in 1953, is mandatory reporting of all new cases of cancer in the population,19 thus justifying its use for epidemiologic and clinical research. Annually, the registry receives approximately 80,000 reports consisting of clinical forms from hospitals; copies of cytology, biopsy, and autopsy reports from pathology laboratories; and records on the cause of death from Statistics Norway (formerly the Central Bureau of Statistics). These forms provide data on new cases and give additional information on previously registered patients with cancer, including death certificates specifying the cause of death. Reporting dysplastic lesions to the registry is mandatory, as is the concurrent reporting of aneuploid oral premalignant lesions. The completeness of the reporting of patients who were hospitalized with oral cancer, defined as the ratio of patients listed in the Cancer Registry of Norway to those in the hospital-based registries, has been estimated to be 99 percent.19
The nature of the data in the registry enables investigators to reevaluate pathologists' reports, assess the type and grade of cancers, and determine the status of resection margins, the number of relapses, and the stage of disease at the time of the initial diagnosis and at each relapse. The registry's data base is annually checked against Statistics Norway's files. Matching and updating procedures are automated and are based on the system of 11-digit personal identification numbers used in Norway, facilitating the assessment of new cancers and cancer-specific mortality.
Statistical Analysis
We used event charts to evaluate the history of each patient.20 The Kaplan–Meier method was used to construct survival curves according to ploidy status.21 The designated end point was death from oral squamous-cell carcinoma. Data on a patient were censored in the Kaplan–Meier estimate if the patient died of unrelated disease or was alive at the end of follow-up. The log-rank test was used to assess the prognostic value of ploidy status in relation to disease-free survival and cancer-specific survival. Differences in proportions were evaluated by means of the chi-square test or Fisher's exact test. All P values were calculated on the basis of two-sided tests, and P values of 0.05 or less were considered to indicate statistical significance. SPSS statistical software (SPSS) and S-PLUS software (Insightful) were used for the calculations.
Results
Characteristics of the Patients
The base-line characteristics of the patients, the number of biopsies, and the number of follow-up visits before carcinomas developed have been reported previously.15 Table 1Table 1
Characteristics of 150 Patients According to the Ploidy Status of Their Oral Leukoplakia. summarizes the main clinical characteristics of the patients. All patients were routinely evaluated every six months. Indications for a biopsy at follow-up visits were the same for all patients and included the occurrence of new lesions or a change in the clinical appearance of a previously identified lesion. All cancers considered in this study were oral squamous-cell carcinomas.Development of Carcinoma from Leukoplakia
Figure 1AFigure 1
Course of Events in 150 Patients with Dysplastic Oral Leukoplakia from the Time of the First Biopsy (Panel A) and Course of Events from the Time of the Development of the First Cancer in the 47 Patients with Oral Cancers (Panel B), According to Ploidy Status. shows the course of events in all 150 patients according to ploidy status. All patients had at least three years of follow-up data that could be evaluated for the development of oral cancer. We previously reported that a carcinoma developed in 36 of 150 patients with oral leukoplakia during a follow-up period that extended to June 30, 2000, and that in some cases exceeded 10 years.15 During the current three-year extension of that study, we found that a carcinoma developed in an additional 11 of the 150 patients, including 2 patients with initially diploid lesions in whom first new aneuploid lesions and then cancer subsequently developed. During a mean follow-up of 80 months (range, 4 to 237), oral carcinoma developed in 47 of 150 patients with dysplastic oral leukoplakia: 5 patients with diploid lesions, 16 patients with tetraploid lesions, and 26 patients with aneuploid lesions (Figure 1A, Figure 2Figure 2Clinical Course of Oral Leukoplakia, According to the Presence (Aneuploidy and Tetraploidy) or Absence (Diploidy) of Markers of Genomic Instability., and Figure 3BFigure 3
Kaplan–Meier Estimates of Cancer-free Survival According to the Margin Status after Resection of Leukoplakia (Panel A) and the Leukoplakia Ploidy Status (Panel B) among All 150 Patients and Estimates of Survival Free from New Cancers (Panel C) and Overall Survival (Panel D) among the 47 Patients with Primary Oral Cancer, According to the Ploidy Status of the Prior Leukoplakia.).Leukoplakia Resection Margins
Among the 150 patients, 37 had positive margins after the initial resection of the leukoplakia and 113 had negative margins. The percentage of positive margins was similar among the diploid, tetraploid, and aneuploid groups (25 percent, 25 percent, and 22 percent, respectively). A carcinoma developed in 32 percent of the patients with negative resection margins (36 of 113), as compared with 30 percent of the patients with positive margins (11 of 37). The margin status of the initial leukoplakia resection had no relation to the development of oral cancer (P=0.95 by the log-rank test) (Figure 3A).
Topographic Relations between Leukoplakias and Subsequent Carcinomas
Cancer developed in the same SNOMED-coded location as the preceding leukoplakia in 79 percent of patients with oral cancer (37 of 47) (Figure 4Figure 4
Topographic Relations between Oral Leukoplakias and Subsequent Oral Carcinomas.).16 With respect to the ploidy status, cancer developed in the same location as the preceding leukoplakia in all 5 patients with diploid lesions (3 carcinomas in the buccal mucosa and 2 in the floor of the mouth) (Figure 4A), in 13 of 16 patients with tetraploid lesions (10 of 11 carcinomas at the lateral border of the tongue and 3 of 5 carcinomas in the floor of the mouth) (Figure 4B), and in 19 of 26 patients with aneuploid lesions (13 of 15 carcinomas in the floor of the mouth and 6 of 11 carcinomas in the lateral border of the tongue) (Figure 4C). Twenty-one percent of the oral carcinomas (10 of 47) developed in a location different from that of the preceding leukoplakia (Figure 4D). The mean distance between these carcinomas and the prior leukoplakias was 4.5 cm, with a range of 3.0 to 8.5 cm.Clinical Course of Patients in Whom a Carcinoma Developed
Figure 1B shows the clinical course for the 47 patients in whom a carcinoma developed. The date of the first oral cancer was set as time 0, and the time to subsequent cancers, the last follow-up visit, or death was plotted. Among these 47 patients, 26 (55 percent) had a subsequent cancer. Of the five patients with carcinomas that arose from diploid leukoplakia, none had a subsequent cancer (Figure 2). A subsequent cancer developed in 4 of 16 patients with tetraploid oral leukoplakia. Two of these patients had one new cancer, and two had two new cancers of the oral cavity. In all four patients, the initial tumors were at the lateral border of the tongue and the subsequent carcinomas developed in a similar site. None died from their cancer during a mean follow-up of 63 months (range, 32 to 128). Of 26 patients in whom oral carcinoma developed from aneuploid leukoplakia, 22 (85 percent) had subsequent or new cancers (total number of cancers, 37) (Figure 1B and Figure 2), and in 8 of these 22 patients (36 percent) the new oral cancers developed at sites that differed from those of the previous cancer.
The percentages of new cancers in the three ploidy groups were strikingly different: 0 percent in the diploid group (0 of 5 patients), 25 percent in the tetraploid group (4 of 16), and 85 percent in the aneuploid group (22 of 26) (P<0.001 by Fisher's exact test). The time to the development of a new cancer also differed significantly among the three ploidy groups (Figure 3C) (P<0.001 by the log-rank test).
The clinical stage of the first carcinomas arising from oral leukoplakia was significantly associated with ploidy status. Among the carcinomas that arose from diploid or tetraploid lesions, 14 percent were in clinical stage I, 48 percent were in stage II, 38 percent were in stage III, and 0 percent were in stage IV, as compared with values of 4 percent, 19 percent, 65 percent, and 12 percent, respectively, for carcinomas that arose from aneuploid lesions (Table 2Table 2
Clinical Stage of First Carcinomas That Arose from Oral Leukoplakia, According to Ploidy Status.) (P=0.03).Cancer Treatment
Among the 47 patients with a carcinoma arising from oral leukoplakia, all but 1 had negative resection margins. A total of 12 patients had unilateral lymph-node metastasis and underwent neck dissection. One patient had distant metastasis to the lung and was not treated with definitive surgery. Hence, 45 of 47 patients were considered to have negative resection margins after the initial treatment of their carcinoma. All patients who underwent resection received postoperative radiotherapy (50 Gy, given in 25 fractionated doses, with daily doses of 2 Gy given five days a week). Twelve patients with lymph-node metastasis also received radiation to the neck nodes at levels III and IV by means of a separate anterior portal in the lower portion of the neck. All 12 patients received one of three regimens of chemotherapy at the time of recurrence: 50 mg of methotrexate per square meter of body-surface area every three weeks (4 patients), 100 mg of docetaxel per square meter every three weeks (1 patient), or 100 mg of cisplatin per square meter in combination with 100 mg of fluorouracil per square meter (for five days) every three weeks (7 patients). Treatment did not vary according to ploidy status.
Cancer-Specific Mortality
Of the 47 patients in whom oral cancer developed, only 1 (who had had a diploid leukoplakia) died of a cause unrelated to cancer — trauma 11 years after the initial diagnosis of oral cancer. The overall cancer-specific mortality rate was 45 percent (21 of 47 patients died) during a mean observation period of 76 months (range, 9 to 185) after the first cancer. As expected, a more advanced stage (stage III or IV) at diagnosis was associated with poor survival (P=0.03). Aneuploid lesions, as compared with diploid or tetraploid lesions, were also significantly associated with poor survival (P<0.001) (Figure 3C). The five-year mortality rate for the aneuploid group was 72 percent (95 percent confidence interval, 49 to 85) (Figure 3D). Although patients with stage III or IV cancer were more likely to die of cancer than those with stage I or II, only patients whose carcinomas arose from aneuploid leukoplakia (21 of 26, or 81 percent) died from their cancer during a follow-up of 62 months (range, 9 to 185) (Figure 2 and Figure 3D). The histologic grade did not have a prognostic influence in this study. Thirteen patients had histologic grade I disease at diagnosis, 16 had grade II, and 18 had grade III. Among these patients, 7 (54 percent), 11 (69 percent), and 8 (44 percent), respectively, had new cases of cancer, which resulted in rates of death from cancer of 38 percent (5 of 13 patients with grade I disease died), 56 percent (9 of 16 with grade II), and 39 percent (7 of 18 with grade III).
Discussion
Our results show that the complete resection of oral leukoplakia does not prevent carcinoma and that oral carcinoma arising from aneuploid leukoplakia has aggressive clinical behavior despite the use of standard treatment. We previously reported that oral erythroplakia with aneuploidy, which is rare and aggressive, is associated with a high risk of death,14 and we have now determined the risk of death from cancer associated with oral leukoplakia, a far more common premalignant lesion. The patients with aneuploid leukoplakia had a rate of primary cancer of 96 percent, a rate of new or subsequent cancer of 81 percent, and a rate of death from cancer of 78 percent during the study.
The status of the margins of the initial resection of leukoplakia did not affect the risk of cancer in our study. The percentage of patients with positive margins was approximately the same in the group with a poor prognosis (as defined by tetraploidy or aneuploidy) and the group with a more favorable prognosis (as defined by diploidy). We could not assess the margin status of the resection of the first carcinoma as an independent prognostic factor because all but two tumors had negative resection margins. The histologic grade of carcinomas according to the criteria of the World Health Organization did not have a prognostic effect, which corroborates previous findings.22
The high overall rate of primary cancer in the same oral location as the prior dysplastic leukoplakia (79 percent) provides topographic evidence of the presence of clonal alterations at histologically negative resection margins.23 The fact that 10 patients had cancer and prior leukoplakia in different locations suggests that the cancer either was genetically distinct from the resected leukoplakia or resulted from the lateral clonal spread of the leukoplakia.5,7
Several of our results suggest that aneuploidy is associated with a biologically more aggressive cancer. Subsequent cancers were more frequently multiple and distant (within the oral cavity) in patients with aneuploid lesions than in those with tetraploid lesions (no subsequent cancers occurred among patients with diploid lesions). The stage of cancer was more advanced in association with aneuploid leukoplakia than with diploid or tetraploid leukoplakia. Since routine treatment and follow-up of all patients with dysplastic leukoplakia were the same regardless of ploidy status,15 the association between the ploidy status and the clinical stage of first carcinomas was probably due to the more aggressive behavior of the tumor in the aneuploid group. The more advanced stage could explain, in part, the poorer survival among the patients with aneuploid lesions than among those with diploid or tetraploid lesions. Furthermore, only patients with aneuploid lesions died of cancer, suggesting that the aneuploidy-related cancers were more lethal than were diploidy- or tetraploidy-related cancers of the same stage.
The development of oral cancer is related to exposure to tobacco24-27 and involves field carcinogenesis and multifocal lesions.5,8,28-31 New cancers in patients with primary oral cancers arise through a complex process of recurrence and the development of second primary cancers.30,31 This process involves the independent development of malignant clones as well as lateral spread of premalignant and malignant cells within the epithelium.5,7,28 Previous studies have shown that other biomarkers of genomic instability, such as chromosomal polysomy and microsatellite alterations, can predict the likelihood of malignant transformation of oral premalignant lesions.32 Future studies may provide mechanistic insights into the aggressive behavior of these lesions.
We identified a subgroup of patients with oral leukoplakia, as defined by aneuploidy, a marker of genomic instability, who are at extremely high risk for biologically aggressive carcinomas despite undergoing complete resection. Therefore, aneuploid leukoplakia is tantamount to carcinoma. The failure of current treatment for aneuploid oral leukoplakia to avert cancer shows that patients with such aggressive, high-risk lesions have an unmet medical need. These patients urgently need new, effective treatments and preventive therapies, such as those involving molecular targets, which in this setting would be equivalent to cancer therapy.33,34
Supported in part by grants from the Norwegian Cancer Society (E 03010/002, E 03010/003, and HF-51019), the Research Foundation of the Norwegian Radium Hospital (702526-13 and SE 0207), Astrid and Birger Torstedts Legat (all to Dr. Sudbø), and the National Cancer Institute, National Institutes of Health (CA16672).
We are indebted to Dr. Steinar Thoresen for providing clinical data on the patients; to Dr. Bente Brokstad Herlofson for photographic documentation of oral leukoplakia; and to Kendall Morse and Ruth Puntervold for helpful reading of the manuscript.
Source Information
From the Departments of Medical Oncology and Radiotherapy (J.S., S.S., J.F.E.), Division of Digital Pathology (W.K.), and the Department of Pathology, Division of Cytology (B.R., A.R.), Norwegian Radium Hospital, University of Oslo, Oslo, Norway; the Departments of Clinical Cancer Prevention (S.M.L.), Biostatistics (J.J.L.), Thoracic/Head and Neck Medical Oncology (S.M.L., L.M.), and Pathology and Head and Neck Surgery (A.E.-N.), University of Texas M.D. Anderson Cancer Center, Houston; the Department of Physics (Norwegian University of Science and Technology, Trondheim, Norway (A.S.); and the Department of Oral Biology, University of Oslo, Oslo, Norway (M.B.).
Address reprint requests to Dr. J. Sudbø at the Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Ullernchausséen 70, Montebello, 0310 Oslo, Norway, or at jon.sudbo@rh.uio.no.
- References
References
1
Scully C ,Porter S . ABC of oral health: swellings and red, white, and pigmented lesions. BMJ 2000;321:225-228
CrossRef | Web of Science | Medline2
Tradati N ,Grigolat R ,Calabrese L , et al. Oral leukoplakias: to treat or not? Oral Oncol 1997;33:317-321
CrossRef | Web of Science | Medline3
Zhang L ,Poh CF ,Lam WL , et al. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection. Oral Oncol 2001;37:505-512
CrossRef | Web of Science | Medline4
Chiesa F ,Boracchi P ,Tradati N , et al. Risk of preneoplastic and neoplastic events in operated oral leukoplakias. Eur J Cancer B Oral Oncol 1993;29:23-28
CrossRef5
Braakhuis BJ ,Tabor MP ,Kummer JA ,Leemans CR ,Brakenhoff RH . A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003;63:1727-1730
Web of Science | Medline6
Califano J ,van der Riet P ,Westra W , et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-2492
Web of Science | Medline7
Jang SJ ,Chiba I ,Hirai A ,Hong WK ,Mao L . Multiple oral squamous epithelial lesions: are they genetically related? Oncogene 2001;20:2235-2242
CrossRef | Web of Science | Medline8
Slaughter DP ,Southwick HW ,Smejkal W . Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-968
CrossRef | Web of Science | Medline9
Lee JJ ,Hong WK ,Hittelman WN , et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6:1702-1710
Web of Science | Medline10
Lippman SM ,Hong WK . Molecular markers of the risk of oral cancer. N Engl J Med 2001;344:1323-1326
Full Text | Web of Science | Medline11
O'Shaughnessy JA ,Kelloff GJ ,Gordon GB , et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-346
Web of Science | Medline12
Shafer WG ,Waldron CA . Erythroplakia of the oral cavity. Cancer 1975;36:1021-1028
CrossRef | Web of Science | Medline13
Bouquot JE ,Ephros H . Erythroplakia: the dangerous red mucosa. Pract Periodontics Aesthet Dent 1995;7:59-67
Medline14
Sudbo J ,Kildal W ,Johannessen AC , et al. Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol 2002;20:456-462
CrossRef | Web of Science | Medline15
Sudbo J ,Kildal W ,Risberg B ,Koppang HS ,Danielsen HE ,Reith A . DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001;344:1270-1278
Full Text | Web of Science | Medline16
Côté RA, ed. Systematized nomenclature of medicine. Vol. 1. Numeric index. 2nd ed. Skokie, Ill.: College of American Pathologists, April 1979:61-4.
17
Pindborg JJ, Reichart PA, Smith CJ, van der Waal J. Histological typing of cancer and precancer of the oral mucosa. 2nd ed. Berlin, Germany: Springer-Verlag, 1997:21-6.
18
Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott–Raven, 1997:29-39.
19
Mork J ,Thoresen S ,Faye-Lund H ,Langmark F ,Glattre E . Head and neck cancer in Norway: a study of the quality of the Cancer Registry of Norway's data on head and neck cancer for the period 1953-1991. APMIS 1995;103:375-382
CrossRef | Web of Science | Medline20
Lee JJ ,Hess KR ,Dubin JA . Extensions and applications of event charts. Am Stat 2000;54:63-70
CrossRef | Web of Science21
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science22
Tralongo V ,Rodolico V ,Luciani A ,Marra G ,Daniele E . Prognostic factors in oral squamous cell carcinoma: a review of the literature. Anticancer Res 1999;19:3503-3510
Web of Science | Medline23
Brennan JA ,Mao L ,Hruban RH , et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:429-435
Full Text | Web of Science | Medline24
Decker J ,Goldstein JC . Current concepts in otolaryngology: risk factors in head and neck cancer. N Engl J Med 1982;306:1151-1155
Full Text | Web of Science | Medline25
Reibel J . Tobacco and oral diseases: update on the evidence, with recommendations. Med Princ Pract 2003;12:Suppl 1:22-32
CrossRef | Web of Science | Medline26
Forastiere A ,Koch W ,Trotti A ,Sidransky D . Head and neck cancer. N Engl J Med 2001;345:1890-1900[Erratum, N Engl J Med 2002;346:788.]
Full Text | Web of Science | Medline27
Vokes EE ,Weichselbaum RR ,Lippman SM ,Hong WK . Head and neck cancer. N Engl J Med 1993;328:184-194
Full Text | Web of Science | Medline28
Braakhuis BJ ,Tabor MP ,Leemans CR ,van der Waal I ,Snow GB ,Brakenhoff RH . Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 2002;24:198-206
CrossRef | Web of Science | Medline29
Mao L ,Lee JS ,Fan YH , et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-685
CrossRef | Web of Science | Medline30
Califano J ,Westra WH ,Meininger G ,Corio R ,Koch WM ,Sidransky D . Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 2000;6:347-352
Web of Science | Medline31
Bedi GC ,Westra WH ,Gabrielson E ,Koch W ,Sidransky D . Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 1996;56:2484-2487
Web of Science | Medline32
Partridge M ,Pateromichelakis S ,Phillips E ,Emilion GG ,A'Hern RP ,Langdon JD . A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000;60:3893-3898
Web of Science | Medline33
Sudbo J . Kjemoprevensjon av munnhulekreft. Tidsskr Nor Laegeforen 2003;123:1518-1521
Medline34
Lippman SM ,Hong WK . Cancer prevention science and practice. Cancer Res 2002;62:5119-5125
Web of Science | Medline
- Citing Articles (41)
Citing Articles
1
Zhonglin Hao, Hui Zhang, John Cowell. (2011) Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumor Biology
CrossRef2
Sang Un Park, Eun Sook Choi, Yeon Sil Jang, Seung-Hee Hong, In-Hoo Kim, Dong Kyung Chang. (2011) Effects of Chromosomal Polyploidy on Survival of Colon Cancer Cells. The Korean Journal of Gastroenterology 57:3, 150
CrossRef3
L. Feller, J. Lemmer. (2011) Cell Transformation and the Evolution of a Field of Precancerization As It Relates to Oral Leukoplakia. International Journal of Dentistry 2011, 1-5
CrossRef4
Jennifer L. Hunt. 2011. Immunohistology of Head and Neck Neoplasms. , 256-290.
CrossRef5
2011. Disorders of the Mucous Membranes. , 783-800.
CrossRef6
I. García-Doval. (2010) Citas inadecuadas en «La leucoplasia oral: Definición de parámetros clínicos, histopatológicos y moleculares y actitud terapéutica» referentes al fraude Sudbo. Actas Dermo-Sifiliográficas 101:3, 284
CrossRef7
A. Martorell-Calatayud, R. Botella-Estrada, J.V. Bagán-Sebastián, O. Sanmartín-Jiménez, C. Guillén-Barona. (2009) La leucoplasia oral: definición de parámetros clínicos, histopatológicos y moleculares y actitud terapéutica. Actas Dermo-Sifiliográficas 100:8, 669-684
CrossRef8
A. Torres-Rendon, R. Stewart, G.T. Craig, M. Wells, P.M. Speight. (2009) DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncology 45:6, 468-473
CrossRef9
Agnieszka M. Rygiel, Francesca Milano, Febo J. ten Kate, John G. de Groot, Maikel P. Peppelenbosch, Jacques J. G. H. M. Bergman, Kauslillia K. Krishnadath. (2008) Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens. Genes, Chromosomes and Cancer 47:5, 396-404
CrossRef10
Tanguy Y. Seiwert, Everett E. Vokes. 2007. Head and Neck Cancer. .
CrossRef11
S. E. Gisvold. (2007) Challenges in scientific publishing ? reflections after 14
years as Editor-in-Chief. Acta Anaesthesiologica Scandinavica 51:8, 975-978
CrossRef12
E.H. van der Meij, H. Mast, I. van der Waal. (2007) The possible premalignant character of oral lichen planus and oral lichenoid lesions: A prospective five-year follow-up study of 192 patients. Oral Oncology 43:8, 742-748
CrossRef13
Kamal-Eldin Ahmed Abou-Elhamd, Tito Naeem Habib. (2007) The flow cytometric analysis of premalignant and malignant lesions in head and neck squamous cell carcinoma. Oral Oncology 43:4, 366-372
CrossRef14
M.D. Mignogna, S. Fedele, L. Lo Russo, C. Mignogna, G. de Rosa, S.R. Porter. (2007) Field cancerization in oral lichen planus. European Journal of Surgical Oncology (EJSO) 33:3, 383-389
CrossRef15
SK Mithani, WK Mydlarz, FL Grumbine, IM Smith, JA Califano. (2007) Molecular genetics of premalignant oral lesions. Oral Diseases 13:2, 126-133
CrossRef16
Curfman, Gregory D., Morrissey, Stephen, Drazen, Jeffrey M., . (2006) Retraction: Sudbø J et al. DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. N Engl J Med 2004;350:1405-13. New England Journal of Medicine 355:18, 1927-1927
Full Text | Original Article 1 | Original Article 217
Chung-Ji Liu, Shu-Chun Lin, Yann-Jang Chen, Kuo-Ming Chang, Kuo-Wei Chang. (2006) Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Molecular Carcinogenesis 45:10, 721-731
CrossRef18
Michele D. Mignogna, Stefano Fedele, Lucio Lo Russo. (2006) Dysplasia/neoplasia surveillance in oral lichen planus patients: A description of clinical criteria adopted at a single centre and their impact on prognosis. Oral Oncology 42:8, 819-824
CrossRef19
Martial Guillaud, John L. Benedet, Scott B. Cantor, Gregg Staerkel, Michele Follen, Calum MacAulay. (2006) DNA ploidy compared with human papilloma virus testing (Hybrid Capture II) and conventional cervical cytology as a primary screening test for cervical high-grade lesions and cancer in 1555 patients with biopsy confirmation. Cancer 107:2, 309-318
CrossRef20
T. Takeda, K. Sugihara, Y. Hirayama, M. Hirano, J-I. Tanuma, I. Semba. (2006) Immunohistological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. Journal of Oral Pathology and Medicine 35:6, 369-375
CrossRef21
Maria Castedo, Arnaud Coquelle, Sonia Vivet, Ilio Vitale, Audrey Kauffmann, Philippe Dessen, Marie O Pequignot, Noelia Casares, Alexandre Valent, Shahul Mouhamad, Elise Schmitt, Nazanine Modjtahedi, William Vainchenker, Laurence Zitvogel, Vladimir Lazar, Carmen Garrido, Guido Kroemer. (2006) Apoptosis regulation in tetraploid cancer cells. The EMBO Journal 25:11, 2584-2595
CrossRef22
Olivier Gires, Brigitte Mack, Jens Rauch, Christoph Matthias. (2006) CK8 correlates with malignancy in leukoplakia and carcinomas of the head and neck. Biochemical and Biophysical Research Communications 343:1, 252-259
CrossRef23
Ann Gillenwater, Vali Papadimitrakopoulou, Rebecca Richards-Kortum. (2006) Oral premalignancy: New methods of detection and treatment. Current Oncology Reports 8:2, 146-154
CrossRef24
B. Swinson, W. Jerjes, M. El-Maaytah, P. Norris, C. Hopper. (2006) Optical techniques in diagnosis of head and neck malignancy. Oral Oncology 42:3, 221-228
CrossRef25
Ning Ma, Toshiro Tagawa, Yusuke Hiraku, Mariko Murata, Xiaohui Ding, Shosuke Kawanishi. (2006) 8-Nitroguanine formation in oral leukoplakia, a premalignant lesion. Nitric Oxide 14:2, 137-143
CrossRef26
Curfman, Gregory D., Morrissey, Stephen, Drazen, Jeffrey M., . (2006) Expression of Concern: Sudbø J et al. DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. N Engl J Med 2004;350:1405-13. New England Journal of Medicine 354:6, 638-638
Full Text27
Maricela Haghiac, Thomas Walle. (2005) Quercetin Induces Necrosis and Apoptosis in SCC-9 Oral Cancer Cells. Nutrition and Cancer 53:2, 220-231
CrossRef28
Giuseppina Campisi, Olga Di Fede, Lucia Giovannelli, Giuseppina Capra, Immacolata Greco, Francesco Calvino, Ada Maria Florena, Lorenzo Lo Muzio. (2005) Use of fuzzy neural networks in modeling relationships of HPV infection with apoptotic and proliferation markers in potentially malignant oral lesions. Oral Oncology 41:10, 994-1004
CrossRef29
J Sudbø, JJ Lee, SM Lippman, J Mork, S Sagen, N Flatner, A Ristimäki, A Sudbø, L Mao, X Zhou, W Kildal, JF Evensen, A Reith, AJ Dannenberg. (2005) RETRACTED: Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. The Lancet 366:9494, 1359-1366
CrossRef30
Nidhi Rohatgi, Jatinder Kaur, Anurag Srivastava, Ranju Ralhan. (2005) Smokeless tobacco (khaini) extracts modulate gene expression in epithelial cell culture from an oral hyperplasia. Oral Oncology 41:8, 806-820
CrossRef31
Umberto Veronesi, Bernardo Bonanni. (2005) Chemoprevention: From research to clinical oncology. European Journal of Cancer 41:13, 1833-1841
CrossRef32
Frank Schwarz, Dimitra Maraki, Sebnem Yalcinkaya, Katrin Bieling, Alfred Böcking, Jürgen Becker. (2005) Cytologic and DNA-cytometric follow-up of oral leukoplakia after CO2- and Er:YAG-laser assisted ablation: A pilot study. Lasers in Surgery and Medicine 37:1, 29-36
CrossRef33
Jon Sudbø, Albrecht Reith. (2005) Retracted: The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. International Journal of Cancer 115:3, 339-345
CrossRef34
Olguta Gologan, E Leon Barnes, Jennifer L Hunt. (2005) Potential Diagnostic Use of p16INK4A, a New Marker That Correlates With Dysplasia in Oral Squamoproliferative Lesions. The American Journal of Surgical Pathology 29:6, 792-796
CrossRef35
Terry A. Day, Angela Chi, Brad Neville, James R. Hebert. (2005) Prevention of head and neck cancer. Current Oncology Reports 7:2, 145-153
CrossRef36
Monica A. Fisher, Jerry E. Bouquot, Brent J. Shelton. (2005) Assessment of risk factors for oral leukoplakia in West Virginia. Community Dentistry and Oral Epidemiology 33:1, 45-52
CrossRef37
Keith D. Hunter, E. Ken Parkinson, Paul R. Harrison. (2005) Opinion: Profiling early head and neck cancer. Nature Reviews Cancer 5:2, 127-135
CrossRef38
James L. Abbruzzese, Scott M. Lippman. (2004) The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 6:4, 321-326
CrossRef39
(2004) Dysplastic Leukoplakia. New England Journal of Medicine 350:26, 2718-2719
Full Text40
Greenspan, Deborah, Jordan, Richard C.K., . (2004) The White Lesion That Kills — Aneuploid Dysplastic Oral Leukoplakia. New England Journal of Medicine 350:14, 1382-1384
Full Text41
Li Mao, Waun K Hong, Vassiliki A Papadimitrakopoulou. (2004) Focus on head and neck cancer. Cancer Cell 5:4, 311-316
CrossRef
- Letters
